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NLR family proteins play important roles in innate
immune response. NOD1 (NLRC1) activates various
signaling pathways including NF-kB in response to
bacterial ligands. Hereditary polymorphisms in the
NOD1 gene are associated with asthma, inflamma-
tory bowel disease, and other disorders. Using
a high throughput screening (HTS) assay measuring
NOD1-induced NF-kB reporter gene activity, fol-
lowed by multiple downstream counter screens
that eliminated compounds impacting other NF-kB
effectors, 2-aminobenzimidazole compounds were
identified that selectively inhibit NOD1. Mechanistic
studies of a prototypical compound, Nodinitib-1
(ML130; CID-1088438), suggest that these small
molecules cause conformational changes of NOD1
in vitro and alter NOD1 subcellular targeting in cells.
Altogether, this inaugural class of inhibitors provides
chemical probes for interrogating mechanisms
regulating NOD1 activity and tools for exploring the
roles of NOD1 in various infectious and inflammatory
diseases.
INTRODUCTION
NLRs (NACHT and leucine-rich repeat domain-containing
proteins) constitute a prominent family of innate immunity
proteins found in mammals (Kanneganti et al., 2007; Ting et al.,
2008). NLR family members, NOD1 (NLRC1, CARD4, or
CLR7.1) and NOD2 (NLRC2, also CARD15; CD; BLAU; IBD1;
PSORAS1; CLR16.3), are of particular interest because they
recognize distinct structures derived from bacterial peptidogly-
cans (PGs) and activate various signaling pathways important
for host defense and inflammation, including NF-kB, stress
kinases, and interferon response factors (IRFs) (Pandey et al.,
2009; Strober et al., 2006; Watanabe et al., 2010).
NOD1 polymorphisms are associated with several human
inflammatory disorders, including sarcoidosis, Crohn’s disease,
asthma, and autoimmune uveitis (Carneiro et al., 2008; Eckmann
and Karin, 2005; Franchi et al., 2008; Strober et al., 2006; TattoliChemistry & Biology 18,et al., 2007). Recently, NOD1 has additionally been implicated
in neuroinflammatory processes involved in the progression
of multiple sclerosis (MS) (Shaw et al., 2011). In an animal model
of MS (experimental autoimmune encephalomyelitis), Nod1/
mice show markedly reduced incidence of hindlimb paralysis,
decreased axon demyelination, and diminished neuroinflamma-
tory infiltrates (Shaw et al., 2011). NOD1 has also been impli-
cated in vascular inflammation. NOD1 activation stimulates
cytokine production by human coronary artery endothelial cells
in culture. Moreover, administration of NOD1 agonists into
mice induces coronary arteritis, with dense cellular infiltrates
(i.e., neutrophils and macrophages), showing histopathological
similarity to the acute phase of Kawasaki disease—a rare
childhood disease characterized by inflammation of blood
vessels (vasculitis) (Nishio et al., 2011). A mouse model of
NOD1-induced ocular inflammation (uveitis) has also been
reported (Rosenzweig et al., 2009). Thus, access to chemical
NOD1 inhibitors would empower research on defining the
role of this NLR family protein in numerous acute and chronic
inflammatory diseases, allowing for an exploration of whether
novel therapeutic interventions based on targeting this class of
proteins are feasible.
Here, we describe the identification of a series of 2-aminoben-
zimidazole derivatives that selectively inhibit NOD1. We have
developed and optimized a cell-based high throughput screen-
ing (HTS) assay platform in which either NOD1 or NOD2 activa-
tion stimulates a NF-kB-responsive luciferase reporter gene.
Various downstream counter screens, combined with insights
provided by cheminformatics analysis, were further applied to
validate the 2-aminobenzimidazole scaffold as an inaugural
family of NOD1-specific inhibitors.
RESULTS AND DISCUSSION
HTS Campaign Identifies NOD1 Inhibitors
Wedevisedcell-basedHTSassaysutilizingaNF-kB-driven lucife-
rase reporter gene as a measure of NOD1 or NOD2 activity. For
the NOD1 assay, HEK293T cells were stimulated with NOD1
ligand, Ala-g-Glu-diaminopimelic acid (g-tri-DAP) (Chamaillard
et al., 2003; Girardin et al., 2003), a component of PG, relying
on endogenous NOD1 expression to result in NF-kB reporter
gene activation (PubChem AID 1578). The Z0 values for the opti-
mized assay performed in either 384- or 1536-well format were
consistently in the range of 0.67–0.73. The NOD2 assay utilized825–832, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 825
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2-Aminobenzimidazoles Inhibit NOD1stable overexpression of NOD2 in HEK293T cells, which em-
ployed the same NF-kB luciferase reporter gene and which
was also optimized to Z0 factor >0.5 in both 384- and 1536-
well formats (PubChem AID 1566).
The NIH library (300,000 compounds) was screened at an
average concentration of 4 mM using the NOD1 and NOD2
HTS assay in 1536-well format to identify candidate inhibitors
based on NF-kB reporter gene activity (see Figures S1 and S2
available online). Hits were counter screened to eliminate cyto-
toxic compounds (false-positives) and, using cheminformatic
filters to eliminate historically promiscuous bioactives, 2481
hits were identified that inhibited either NOD1, NOD2, or both
(Figure S3A). These hits were then further tested at the same
concentration against the same HEK293T-NF-kB luciferase
cells stimulated with TNFa to induce NF-kB by an alternative
means (PubChem AID 1852), thus eliminating 1286 nonspecific
compounds. The hit compounds were reordered and retested,
reducing the confirmed hits to 536 compounds. Testing of
these compounds in dose-response experiments, using both
NOD1 and NOD2 NF-kB reporter gene assays, revealed 309
hits with IC50%10 mM and with little or no cytotoxicity at 20 mM
(PubChem AID 2335). Counter screening the NOD1 and NOD2
hits against each other revealed 183 compounds showingR10-
fold target selectivity of NOD1 over NOD2 (Figure S3B).
Compounds that inhibited NOD2 will be described elsewhere.
Pathway Selectivity Assays Reveal NOD1-Selective
Inhibitors
Several cell-based assays were developed to differentiate com-
pounds that inhibit NF-kB induction by other upstream activators
from NOD1/NOD2 selective compounds. For instance using the
same HEK293T-NF-kB-luciferase cells, we compared the ability
of compounds to suppress NF-kB activity induced by NOD1
ligand (g-tri-DAP), NOD2 ligand (muramyl dipeptide [MDP]),
TNFa, protein kinaseCactivators (phorbolmyristic acetate [PMA]
and ionomycin), and DNA-damaging agents (doxorubicin) (Fig-
ures 1A and 1B). Consistently, a series of 2-aminobenzimidazole
derivatives (Table S1) inhibited NF-kB activation only after
g-tri-DAP treatment (Figures 1A and 1B), thus showing promise
as potential NOD1-specific NF-kB inhibitors.
A structure activity relation (SAR) analysis was initiated by both
analog-by-catalog approach and internal medicinal chemistry
effort, wherein a total of 78 compounds were synthesized.
Interestingly, we observed that the presence of 2-amino and
sulfonamide functionality on the benzimidazole ring is pertinent
for the bioactivity of these compounds (Table S1). In general,
electron-donating groups on the aromatic ring resulted in more
potent and selective compounds. A detailed description of
SAR andmedicinal chemistry effort will be described separately.
To extend the analysis of the candidate NOD1 inhibitors
beyond reporter gene assays, we also measured the levels of
a NF-kB-inducible cytokine, interleukin-8 (IL-8). Using a recently
described assay employing breast cancer MCF-7 cells overex-
pressing NOD1 or NOD2 (da Silva Correia et al., 2006), we
measured IL-8 secretion into culture supernatants following
stimulation with NOD1 ligand (g-tri-DAP), NOD2 ligand (MDP),
or TNFa (Figure 1C). Again, 2-aminobenzimidazole series com-
pounds selectively inhibited IL-8 production induced by NOD1
ligand, but not other stimuli (Figure 1C), with compound CID-826 Chemistry & Biology 18, 825–832, July 29, 2011 ª2011 Elsevier L1088438 representing the most potent of the analogs. Cell
viability was not affected by CID-1088438 under diverse cell
treatments (Figure S4). CID-1088438 also inhibited g-tri-DAP-
induced expression of the prototypical NF-kB target gene IkBa
at the mRNA level (Figure S5). Indeed, CID-1088438 inhibits
g-tri-DAP-dependent activation of NF-kB (IkBa phosphorylation
and degradation) and MAPK (p38 phosphorylation) signaling,
without affecting Akt survival pathway (Figure S6), consistent
with the known roles of NOD1 in signal transduction (Allison
et al., 2009; Inohara et al., 1999; Opitz et al., 2006; Tattoli
et al., 2007).
In addition to NLRs, Toll-like receptors (TLRs) and RIG-I-like
receptors (RLRs) constitute important families of pathogen
receptors (Creagh and O’Neill, 2006). Human myelomonocytic
THP-1 cells containing a NF-kB/AP-1-inducible reporter gene
encoding secreted alkaline phosphatase (SEAP) were employed
for convenient monitoring of NF-kB activity. After inducing diffe-
rentiation with PMA, THP.1 macrophages were treated for 24 hr
with CID-1088438 or its inactive analog (CID-44229067, Table
S1) and various TLR agonists, assessing effects on NF-kB-
inducible SEAP activity. No inhibitory effects of CID-1088438
were observed for any of the TLR agonists tested (TLR1, 2, 4,
5, 6, and 8) (Figure 2A). Note that, while the NOD1 ligand
g-tri-DAP is a weak inducer of NF-kB activity in THP.1 macro-
phages, inhibition by CID-1088438 was highly reproducible.
A noncanonical NF-kB pathway stimulated by certain TNF
family members, including B cell-activating factor (BAFF),
involves ubiquitin-mediated processing of the NF-kB subunit
p100 to p52 and is dependent on phosphorylation of p100 by
IkB kinase (IKK) subunit IKK1 (or IKKa) (Claudio et al., 2002;
Tergaonkar, 2006). Using 697 pre-B leukemia cells containing
a NF-kB-luciferase reporter gene, we verified that the noncanon-
ical NF-kB activation induced by BAFF (Claudio et al., 2002)
is not inhibited by CID-1088438 (Figure 2B), whereas NF-kB
activity induced by NOD1 ligand g-tri-DAP is inhibited. CID-
1088438 also did not inhibit NF-kB activity induced by TLR9
ligand CpG DNA in these cells (Figure 2B).
The RLRs comprise a family of cytoplasmic RNA helicases that
include RIG-I (retinoic acid-inducible protein I), and MDA-5
(melanoma differentiation-associated gene 5), implicated in viral
double-strand RNA recognition (Creagh andO’Neill, 2006). RIG-I
and MDA-5 bind the mitochondrial membrane protein MAVS
to initiate a signaling cascade that includes induction of type I
interferon (IFN) response (Seth et al., 2006). In addition to stimu-
lating NF-kB, NOD1 also binds MAVS to stimulate IFN produc-
tion by activating IRFs (Watanabe et al., 2010). Using HEK293T
cells stably containing an IFN-sensitive response element
(ISRE)-driven luciferase reporter gene, we tested the effects of
compound CID-1088438 on several IFN inducers, including
NOD1 ligand g-tri-DAP, poly(I:C), poly(dA:dT), and a RNA virus
(Sendai virus). Although CID-1088438 suppressed ISRE-driven
reporter gene activity induced by g-tri-DAP, no inhibition was
observed for the other IFN response stimuli (Figure 2C). In
contrast the inactive analog CID-44229067 did not inhibit g-tri-
DAP-induced ISRE reporter gene activity (Figure 2C). These
results further confirm the selectivity of the NOD1 inhibitory
2-aminobenzimidazole compounds, and also indicate that they
act upstream of the divergence of the NF-kB and IFN-dependent
pathways activated by NOD1.td All rights reserved
Figure 1. Profiling 2-Aminobenzimidazole Derivatives for Pathway Selectivity
(A) HEK293T NF-kB-luciferase cells (6000 cells/well in 1536-well plate) were treated with 0.75 mg/ml g-tri-DAP, 0.7 mg/ml MDP, or 0.1 ng/ml TNFa for 14 hr, in
the presence of increasing amounts (in molar, M) of the selected compounds (cmpd). Luciferase activity data were used to calculate percent inhibition
(mean ± standard error of the mean [SEM], n = 2).
(B) NF-kB-luciferase-containing cells were treated with 5 mg/ml g-tri-DAP, 0.4 mg/ml doxorubicin, or 10 ng/ml PMA/ionomycin for 18 hr (10,000 cells/well in
384-well plate), measuring luciferase activity and calculating percent (%) of inhibition (mean ± standard deviation [SD], n = 3).
(C) MCF-7 cells stably expressing NOD1, NOD2, or GFP (50,000 cells/well in 96-well plate) were treated with 5 mg/ml g-tri-DAP, 5 mg/ml MDP, or 5 ng/ml TNFa,
supplemented with 1.5 mg/ml cycloheximide, for 24 hr, in the presence of increasing amounts of the selected compounds. IL-8 levels were quantified by ELISA.
Data represent mean ± SD (n = 3). Two-dimensional structures of selected compounds are shown (see Table S1 for complete SAR).
See also Figures S1–S5 and S7.
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2-Aminobenzimidazoles Inhibit NOD1Many NLRs form complexes with caspase-1, creating so-
called ‘‘inflammasomes’’ responsible for proteolytic processing
of inflammatory cytokine interleukin-1-beta (IL-1b) (Martinon
and Tschopp, 2007; Pe´trilli et al., 2007). CID-1088438 did not
inhibit IL-1b secretion induced by various inflammasome activa-
tors (Figure 2D; Figure S7), indicating a lack of promiscuity
toward other NLRs.
CID-1088438 Selectively Inhibits Responses of Primary
Dendritic Cells (DCs) to NOD1 Ligand
To extend the analysis of CID-1088438 beyond immortalized
cell lines to primary cells, we performed experiments using
ex vivo cultures of human monocyte-derived DCs. DCs were
activated with either g-tri-DAP or lipopolysaccharide (LPS), in
the presence or absence of active compound CID-1088438.Chemistry & Biology 18,CID-1088438 reduced cell surface expression of costimulatory
molecules CD83, CD86, and HLA-DR (Figure 2E) and also
inhibited expression of IL-1b, IL-6, and TNFa (Figure 2F) elicited
by g-tri-DAP (but not by LPS), without causing cytotoxicity. No
significant changes in NOD1 expression levels were observed
(Figure 2F).
Mechanisms of Chemical Inhibitors of NOD1
NOD1 activates NF-kB in partnership with various interacting
proteins, particularly RIP2, IAPs, and IKKg/NEMO (Bertin et al.,
1999; Hasegawa et al., 2008; Inohara et al., 1999; Krieg et al.,
2009; Stehlik et al., 2003), wherein NOD1 binds directly to
RIP2, which in turn interacts with IAPs, forming a complex that
stimulates IKK activation (Krieg and Reed, 2010). Gene transfec-
tion experiments suggested that CID-1088438 targets NOD1825–832, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 827
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Figure 2. CID-1088438 Specifically Inhibits NOD1-Dependent Signaling Pathways
(A) PMA-differentiated THP.1 cells containing NF-kB-driven SEAP (105 cells/well in 96-well plate) were cultured with or without 5 mM CID-1088438
or CID-44229067 and various TLR/NLR inducers: 0.5 mg/ml Pam3CSK4 (TLR1/TLR2), 5 3 107 cells/ml HKLM (TLR2), 1 mg/ml FSL-1 (TLR6/2), 0.5 mg/ml LPS
(TLR4), 0.5 mg/ml Flagellin (TLR5), 1 mg/ml ssRNA40 (TLR8), 5 mg/ml g-tri-DAP (NOD1), 5 mg/ml MDP (NOD2), or 5 ng/ml TNFa. After 24 hr incubation,
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2-Aminobenzimidazoles Inhibit NOD1signaling upstream of RIP2 (Figure 3A). No significant impact of
the compound was observed in cells overexpressing IKKg/
NEMO, MYD88, FLIP, CARD6, APAF1, or NLRC4 (data not
shown), confirming its specificity.
To examine whether CID-1088438 binds NOD1, we expressed
and purified recombinant NOD1 protein from human cells and
performed one-dimensional nuclear magnetic resonance (1D
1H-NMR) spectroscopy as a means to examine ligand binding.
Indeed, the proton (1H) signal intensity derived from CID-
1088438 was suppressed in the presence of NOD1 but not
variouscontrolproteins suchasBcl-XLandBid, therebydemons-
trating direct interaction between this compound and NOD1
protein (Figure 3B). However, the spectrum of the inactive analog
compound CID-44229067 was also suppressed by NOD1
protein (not shown), which suggests that this compound may
also bind NOD1 but fails to suppress its cellular activity. Similar
results were obtained by affinity selection mass spectrometry
(not shown). Interestingly, CID-1088438 did not interfere with
ATP binding to recombinant NOD1 protein (Figure S8).
We obtained evidence that CID-1088438 may alter the confor-
mation of NOD1 protein in vitro. For example, in experiments
using purified His6-tagged NOD1, addition of active compound
CID-1088438 but not inactive analog CID-44229067, markedly
increased the relative amount of His6-NOD1 protein that bound
to nickel-chelating resin (Ni/NTA) without affecting the binding
of other His6-tagged control proteins such as Bcl-XL and Bid
(Figure 3C). Similar results were obtained when CID-1088438
was added to living cells expressing His6-FLAG-NOD1 protein
(Figure 3D). In contrast, this compound had no effect on the
efficiency that His6-myc-NOD2 protein was pulled down by
Ni/NTA (Figure 3D). Interestingly, NOD1 ligand g-tri-DAP also
impacted the efficiency with which His6-FLAG-NOD1 protein
was pulled down with Ni/NTA, reducing the relative amount of
NOD1 protein recovered from cells treated with either inactive or
active compounds without changing total levels of His6-FLAG-
NOD1 protein in lysates (Figure 3D). Addition of proteasome-
inhibitor MG132 largely negated the effects of both g-tri-DAP
and compounds on His6-FLAG-NOD1 pull-down by Ni/NTA,
suggesting a role also for ubiquitination in controlling NOD1
protein conformation. Indeed, we have obtained evidence that
NOD1 undergoes both lysine 48 (K48) and K63-linked polyubiqui-
tination (Figure S9).SEAP activity in culture supernatants was measured, expressing data as percen
n = 2).
(B) Pre-B 697 cells stably containing a NF-kB-luciferase reporter gene (105 cells/w
44229067, in combination with 20 mg/ml g-tri-DAP, 100 ng/ml BAFF, or 5 mM ODN
(C) 293T cells, stably expressing luciferase reporter gene driven by IFN responsiv
CID-1088438 or CID-44229067, in combination with 10 mg/ml g-tri-DAP (NOD1), 1
Poly(dA:dT) (LyoVec) (IRF3), or Sendai Virus (classical IRF3 inducer). Luciferase
(D) RAW264.7 cells (5 3 104 cells/well in 96-well plate) were treated with 5 mM of
urate (MSU), 1 mg/ml poly(dA:dT), or 1 mg/ml LPS plus 5 mM ATP, after LPS pret
multiplicity of infection (MOI) of 20 and 200 bacteria permammalian cell. Supernat
IL-1b levels were quantified by ELISA (mean ± SD; n = 3).
(E) DCswere activatedwith either 5 mg/ml g-tri-DAP or 100 ng/ml LPS, in the prese
performed for CD83, CD86, and HLA-DR markers. Representative data from one
(F) Expression of prototypical NF-kB target genes in primary monocyte-derived
presence or absence of 15 mMCID-1088438. After 4 hr, relative mRNA expression
were normalized according to b-actin levels (mean ± SEM of three donors).
See also Figures S1–S11.
Chemistry & Biology 18,Next, we interrogated the effects of CID-1088438 on endoge-
nous NOD1 protein. Because endogenous NOD1 is present at
low levels and very difficult to detect with currently available anti-
bodies, we enriched NOD1 protein from lysates of HCT-116 cells
by immunoprecipitation, then analyzed NOD1 levels by immuno-
blotting. In unstimulated cells, no clear difference in the levels of
NOD1 protein was observed following treatment with active
compoundCID-1088438 or inactive analogCID-44229067 (Figu-
re 3E). However, culturing cells with g-tri-DAP resulted in a
decline in NOD1 protein levels in cells treated with DMSO control
or inactive compound but not active compound. Changes in
NOD1 protein levels did not correlate with significant alterations
in NOD1 (or NOD2 and RIP2) mRNA expression (Figure S5).
Upon activation by bacterial ligands, NOD1 is reported to oli-
gomerize and form complexes with various cytosolic proteins,
including RIP2, SGT-1, IAPs, and Bid (da Silva Correia et al.,
2007; Inohara et al., 1999; Krieg et al., 2009; Krieg and Reed,
2010; Yeretssian et al., 2011). However, CID-1088438 did not
interfere with NOD1 association with RIP2, Bid, or SGT-1 under
overexpressing conditions (Figures S10 and S11; data not
shown), suggesting that direct interference with protein-protein
interactions is unlikely to explain the mechanism of this NOD1
inhibitory compound.
NOD1 is reported to traffic between membranes and cytosol
(Kufer et al., 2008; Le´cine et al., 2007), correlating with NF-kB
activation. Therefore, we performed subcellular fractionation
analysis of MCF-7 cells stably expressing epitope-tagged
NOD1 (Figure 3F) or NOD2 (Figure S12), which are conveniently
detected by immunoblotting using epitope-specific antibodies.
Cells were treated with or without the respective NOD1 or
NOD2 activators (g-tri-DAP or MDP), in the presence or absence
of compounds. Remarkably, CID-1088438 induced enrichment
of NOD1 protein in the membrane fraction, independently of
g-tri-DAP induction. No changes of NOD2 compartmentalization
were observed upon treatment with CID-1088438 or CID-
44229067 (Figure S12). In contrast, CID-1088438 reducedmem-
brane localization of RIP2, a NOD1-binding partner required
for NF-kB induction (Figure 3F, high exposure). These data are
in concordance with reports that migration of RIP2 to the
membrane is essential for stimulating NF-kB signaling (Kufer
et al., 2008; Le´cine et al., 2007). We conclude that CID-
1088438 alters subcellular targeting of NOD1.tage relative to treatment with inducer only (indicated as 100%; mean ± SEM,
ell in 96-well plate) were cultured with or without 10 mM CID-1088438 or CID-
2006 (TLR9). Luciferase activity was measured 24 hr later (mean ± SD; n = 3).
e elements (105 cells/well in 96-well plate), were cultured with or without 5 mM
mg/ml poly(I:C) with lipid transfection reagent (LyoVec) (RIG-I/MDA-5), 1 mg/ml
activity was measured after 24 hr (mean ± SD; n = 4).
CID-1088438 or CID-44229067, then stimulated with 100 ng/ml monosodium
reatment (induction of pro-IL-1b synthesis), or infected with S. typhimurium at
ants were collected after either 2 hr (Salmonella infection) or 4 hr (all others), and
nce or absence of 15 mMCID-1088438. After 24 hr, flow cytometry analysis was
donor are shown (n = 3).
DCs. Cells were treated with either 5 mg/ml g-tri-DAP or 100 ng/ml LPS, in the
of IL-1b, IL-6, TNFa, and NOD1 was determined by quantitative PCR. Results
825–832, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 829
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Figure 3. Analysis of Mechanisms of Chemical Inhibitors of NOD1
(A) HEK293T- NF-kB-luciferase cells were transfected with plasmids encoding NOD1, RIP2, XIAP, or GFP in various combinations. After 24 hr, cells were cultured
with or without 3.5 mg/ml g-tri-DAP, 10 mMof CID-1088438, or combinations of these reagents for 24 hr beforemeasuring luciferase activity. Datawere normalized
according to respective inducer-only (IND) treated cells (100%) (mean ± SD, n = 4).
(B) 1D 1H-NMR spectra were collected for CID-1088438 (50 mM) in the absence (upper spectrum) and presence (lower spectra) of 5 mMof His6-Flag-NOD1, His6-
Bcl-XL, or His6-Bid purified proteins, respectively. CID-1088438-derived proton signal intensity (arrows) is only suppressed in the presence of NOD1, thereby
demonstrating direct interaction between ligand and protein.
(C) Purified His6-Flag-NOD1, His6-Bcl-XL, or His6-Bid proteins (z0.4 mg) were preincubated for 60 min with 20 mM CID-1088438 or CID-44229067 (DMSO
as control). Ni-NTA agarose beads were then added, and the mixture was incubated overnight at 4C. Ni/NTA pull-down was performed, and samples
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2-Aminobenzimidazoles Inhibit NOD1SIGNIFICANCE
We report the characterization of a class of 2-aminobenzimi-
dazole derivatives as the first selective NOD1 inhibitors.
These compounds suppress NF-kB signaling induced by
NOD1, but not by multiple other NF-kB activators tested,
including NOD2, TLRs, TNF family cytokines, RNA receptors
(MAVS-activators), DNA damaging agents, and PKC activa-
tors. The active 2-aminobenzimidazoles also selectively
interfere with the NOD1-mediated stimulation of stress
kinases and the interferon response pathway. Our studies
of the mechanisms of CID-1088438 (ML130), hereafter
dubbed Noditinib-1, suggest that this compound modulates
NOD1 conformation and alters its subcellular localization.
As such, Noditinib-1 provides a useful research tool for
interrogating the role of NOD1 in human cell specimens
and a chemical probe for improving understanding of
the complex mechanisms regulating NOD1 signaling func-
tions. In this regard, pharmaceutical targeting of down-
stream components of NF-kB signaling results in pathway
nonspecific inhibition, causing broad suppression of host
innate immune defenses and, thus, potentially leaving
patients vulnerable to opportunistic infections. In contrast,
compounds that selectively aim upstream targets/pathways
responsible for NF-kB signaling (such as NOD1) would
be expected to leave most innate immunity defense mecha-
nisms intact but would be efficacious only for diseases
where the specific target/pathway is causally involved in
disease pathogenesis. Further elaboration of the mecha-
nism of Noditinib compounds may reveal new strategies
for achieving a proper balance of innate immunity responses
and restoring health in conditions where NOD1 homeostasis
is disrupted.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
twelve figures, and one table and can be found with this article online at
doi:10.1016/j.chembiol.2011.06.009.
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